covid vaccine pfizer news

Pfizer tops earnings estimates

Pfizer shows profit growth from cost cuts and steadier COVID sales

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after large swings related to its COVID-19 vaccine.

CNBC on MSN · 1d

Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its Covid business and stock price.

Zacks.com on MSN · 1d

Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales

Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded earnings of 10 cents per share in the year-ago quarter.

Pfizer, Covid

Bloomberg L.P. · 1d

Pfizer’s Covid Boost Overshadowed by Kennedy Threat to Vaccines

Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., who has been a vocal opponent of the company’s top-selling shot, got one step closer to becoming US health secretary.

Crain's New York · 1d

Pfizer gets unexpected boost from Covid vaccine and pill

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to fend off criticism from an activist investor that has argued the company squandered its pandemic gains and needs a new path forward.

Politifact · 5d

No, Pfizer didn’t release a new list of COVID-19 vaccine side effects

"Pfizer just released its list of side effects of its COVID-19 vaccine," multiple Facebook posts said Jan. 26 and 27. The posts included a purported list of 46 Pfizer-BioNtech COVID-19 vaccine side effects, including cardiac arrest and neonatal death.

BioPharma Dive2h

GSK, Pfizer sales of RSV shots slow as vaccination rates ebb

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

FiercePharma1d

Pfizer harnesses COVID fluctuations to clinch Q4 gains as RSV vaccine sales plummet

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.” | The company benefited from higher-than-expected sales of ...

11hon MSN

Pfizer's CEO says he's had dinner with Trump's health secretary pick, RFK Jr.

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

devdiscourse2d

Pfizer Faces Pressure Amid Waning COVID-19 Wave

U.S. health experts anticipate a smaller wave of COVID-19 cases this winter, potentially impacting Pfizer's non-COVID ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results